Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) disclosed that the latest data on its drug candidate, REO 017, suggest that it could increase overall survival rate for different periods. The drug was for the treatment of pancreatic cancer and the result was based on Phase two study. The company took the opportunity in ESMO world Congress on Gastrointestinal Cancer to make its presentation on the progress made on its drug candidate.
One-Year Survival Rate
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) indicated the results generated about two-fold increase when it comes to the survival rate for one period. For the two-year period, the survival rates increased to a five-fold compared to the gemcitabine therapy only as evidenced by the historical data.
The company said that the scrutiny of the overall survival benefit coupled with the obvious restricted impact on progression free survival is growing now-a-days. That has also become a characteristic of immune-based treatments of therapeutic. The company said that it is going to incorporate the results of both its new, as well as, the current phases so that the Oncolytics follow overall survival wherever possible.
Survival Analysis
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) said that survival analysts of 33 patients were done and the result indicated median progression free survival (PFS) of four months. The median survival rate was 10.2 months overall. The company said that its data demonstrated the survival rate of 45% for one year and 24% for two years. There is also a possibility of combining Oncolytic viral treatment in future trial with the help of anti-PD-L1 inhibitors.
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) also said that 29 patients were available for clinical response. Twenty-three of them had stable disease while five were having progressive disease. One patient had a partial response. The company’s President and CEO, Brad Thompson, said that this was the second cancer where PDL1 is up regulated and confirmed in target rumors after the collaborators’ early observations of PD-L1 in glioblastoma.
Oncolytics Biotech Inc. (Oncolytics), incorporated on April 2, 1998, is a development-stage company. The Company is focused on research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from reovirus. The virus has been demonstrated in tumor cells bearing an activated Ras pathway. Oncolytics is directing a clinical trial program with the focus of developing REOLYSIN as a human cancer therapeutic. The clinical program includes clinical trials, which it sponsors directly along with Third Party Clinical Trials. Third Party Clinical Trials are clinical trials that are being sponsored by other institutions.
The Company’s clinical trial program has included human trials using REOLYSIN alone, and in combination with radiation and chemotherapy, and delivered via local administration and/or intravenous administration. Oncolytics uses contract toll manufacturers to produce REOLYSIN. The Company has two subsidiaries: Oncolytics Biotech (Barbados) Inc. (OBB), a Barbados company, and Valens Pharma Ltd. Oncolytics Biotech (US) Inc. and Oncolytics Biotech (U.K.) are subsidiaries of OBB.
The post Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) REO 017 Drug Candidate Increases Median Overall Survival Rate appeared first on Live Trading News.